NCT02541383: Phase 3 - Bortezomib, thalidomide, dex +/-Daratumumab before & after ASCT (CASSIOPEIA)

The CASSIOPEIA trial

IFM / HOVON

IFM 2015-01

HOVON HO131 MM

Newly Diagnosed Multiple Myeloma

A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma

The purpose of this study is to evaluate if the addition of daratumumab to Bortezomib, Thalidomide and Dexamethasone will increase the stringent complete response rate after consolidation therapy and increase the progression free survival after daratumumab maintenance therapy in transplant eligible participants with previously untreated Multiple Myeloma.

The Intergroupe Francophone du Myélome and

Dutch-Belgian Cooperative Trial Group for Hematology Oncology.

---

Sponsor

Intergroupe Francophone du Myelome

IFM

Collaborators